STARD4 suppresses tumorigenesis and attenuates enzalutamide resistance via lipid metabolic reprogramming and AR stabilization in prostate cancer
Our findings identify STARD4 as a promising therapeutic target for reversing enzalutamide resistance in PCa while also providing novel insights for future research on lipid metabolism within the tumour microenvironment.
Authors
- Qinzhang Wang (ORCID: https://orcid.org/0000-0002-7202-3282)
- Yi Zhang (ORCID: https://orcid.org/0009-0007-6683-1412)
- Ke Ma (ORCID: https://orcid.org/0000-0002-9716-6968)
- Juan Wang (ORCID: https://orcid.org/0000-0003-0767-5687)
- Qiang Li (ORCID: https://orcid.org/0000-0003-3610-6934)
- Bo Liu (ORCID: https://orcid.org/0000-0002-5450-5528)
- Kai Zeng (ORCID: https://orcid.org/0000-0002-4300-6715)
- Lei Jia
- Xi Wang (ORCID: https://orcid.org/0000-0001-8918-7905)
- Xianglin Yuan
- Qinyu Li (ORCID: https://orcid.org/0000-0003-0862-4451)
Institutions
- Shihezi University (CN)
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1186/s13046-025-03600-7
- Primary Topic
- Cancer, Lipids, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00